BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» NewCo News: Cyrenaic Targets Untreated Schizophrenia Symptoms
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
NewCo News: Cyrenaic Targets Untreated Schizophrenia Symptoms
March 16, 2011
By
Marie Powers
No Comments
Cyrenaic Pharmaceuticals Inc. is a little company with big dreams. The privately held biotech, based in Princeton, N.J., is focused on the development of CYR-101, an antipsychotic in clinical development for the treatment of schizophrenia.
BioWorld